- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Natalizumab – July 2019
Natalizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Tysabri®
Last updated
9 July 2025